**Study Overview:** This study is testing the safety of a new medicine, **anumigilimab**, for adults with **Sickle Cell Disease (SCD)**. SCD is a blood disorder that can cause pain and other serious problems. The study is called "phase 2a," which means it's an early stage to check how safe the medicine is. **How It Works:** Participants will get the medicine through an injection under the skin, known as **subcutaneous (SC)**. The study lasts for **64 weeks**. For the first **12 weeks**, doctors will figure out the best dose for each person. Then, for the next **52 weeks**, that dose will be maintained. **Placebo-controlled** means some people might get a fake treatment for comparison. **Who Can Join:** - You need to be at least **18 years old**. - You must have a confirmed diagnosis of SCD. - You should have had 1 to 12 pain episodes needing medical care in the past year. **Key Points:** - **Duration:** Commitment is for 64 weeks. - **Safety:** Focus is on the safety of the medicine. - **Eligibility:** Must meet specific health criteria to join. This study is important to find safer and more effective treatments for SCD.